# Sagar Lonial

Principais episódios de podcast
Atualizada:

Sagar Lonial, MD, FACP - The MoD Squad in Multiple Myeloma: CELMoDs as New Partners for Innovative Sequential Care in Relapsed/Refractory Disease

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply f…

Sagar Lonial, MD, FACP - The MoD Squad in Multiple Myeloma: CELMoDs as New Partners for Innovative Sequential Care in Relapsed/Refractory Disease

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply f…

Recent Advances, Future Directions, and Ideas on Integrating CELMoDs Into The Care Of Patients With Myeloma

Listen in to learn from Sagar Lonial, MD, and Mohamad Mohty MD, PhD, about the advantages and future implications of the next-generation protein degradation modulator based therapy and find out how to integrate their use into your practice. Presenters:Sagar Lonial, MD, FACP, FASCO Chair and Profe…

Episode 292 - CELMoDs in Myeloma: A Report From EHA

Chadi is joined by two of the world's leading multiple myeloma experts, Dr. Sagar Lonial of Emory University and Dr. Vincent Rajkumar of Mayo Clinic, for an in-depth discussion of the latest advances in multiple myeloma presented at the European Hematology Association (EHA) Congress in Stockholm. T…

EXCALIBER-RRMM - Iberdomide/Dara/Dex FDA Approval for R/R Multiple Myeloma: Dr. Sagar Lonial

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Sagar Lonial, a myeloma specialist from the Emory University, to discuss the recent FDA approval of iberdomide, a novel cereblon modulator (CELMoDs), in combination with daratumumab and dexamethasone for the treatment …

S18 Ep30: FDA Approval Insights: Iberdomide-Based Therapy Adds Another Option for R/R Myeloma: With Sagar Lonial, MD, FACP, FASCO

In today’s episode, we welcomed Sagar Lonial, MD, FACP, FASCO, to discuss the significance of the August 2026 FDA accelerated approval of iberdomide (Zenbexus) plus daratumumab and hyaluronidase-fihj (Darzalex Faspro) and dexamethasone for the treatment of adult patients with relapsed or refracto…

Hema Now: Reimagining Multiple Myeloma Treatment

Sagar Lonial discusses advances in multiple myeloma treatment, the evolving role of immunotherapy and minimal residual disease, unmet needs in relapsed disease, lessons from research, and emerging technologies shaping future care. Timestamps: 00:00 – Introduction 01:24 – Inspiration for Myeloma…

How Iberdomide and CELMoDs Are Transforming Relapsed Myeloma Care

For years, first-relapse myeloma regimens have delivered just 1 to 2 years of progression-free survival and immunomodulatory drugs were dosed to the maximum tolerated dose. Iberdomide, the first CELMoD approved by the FDA and the first myeloma approval based on minimal residual disease negative sta…

Do sporting events make people more inclined to get screened for cancer? We ask Chief Medical Officer of Winship Cancer Institute of Emory University Dr. Sagar Lonial that and more

Sam and Greg are joined by Chief Medical Officer of Winship Cancer Institute of Emory University Dr. Sagar Lonial as the Falcons offer cancer screenings today during Bears-Falcons. Do sporting events make people more inclined to get screened for cancer?

Will the Falcons get a bounce back win against the Bears?

In the second hour, Sam and Greg are joined by Chief Medical Officer of Winship Cancer Institute of Emory University Dr. Sagar Lonial as the Falcons offer cancer screenings today during Bears-Falcons. Is this the perfect time to face Caleb Williams? In the second segment, they’re joined by 92.9 The…